The global giant cell arteritis treatment market size is likely to be valued at US$1.3 billion in 2026 and is expected to reach US$2.0 billion by 2033, growing at a CAGR of 6.2% during the forecast period from 2026 to 2033, driven by the growing burden of age-related autoimmune vasculitis and increasing adoption of targeted biologic therapies.

According to recent clinical and epidemiological studies published in 2024-2026, giant cell arteritis primarily affects adults aged 50 and older, with the highest incidence observed in individuals aged 70-79 years. Research published in Arthritis Research & Therapy reported a pooled global incidence of approximately 10 cases per 100,000 people aged over 50, while Germany-based 2026 data estimated prevalence rates above 140 cases per 100,000 in elderly populations. Rising use of advanced imaging diagnostics and IL-6 inhibitor therapies is supporting long-term disease management and market growth.

Driver - Rising Geriatric Population and Increasing Disease Prevalence

The giant cell arteritis treatment market is significantly driven by the rapid growth of the global elderly population, as the disease predominantly affects adults aged 50 and older. According to the World Health Organization, the population aged 60 years and older is expected to double by 2050, increasing the burden of age-related inflammatory disorders worldwide.

Giant cell arteritis is strongly associated with aging immune systems and vascular inflammation, particularly in developed regions such as North America and Europe. Improved awareness among healthcare professionals and advancements in diagnostic imaging technologies are also contributing to earlier detection rates and higher treatment adoption.

The increasing prevalence of autoimmune and vasculitis-related disorders is further accelerating demand for advanced giant cell arteritis therapies. Clinical studies published in recent years indicate that women and elderly individuals remain at the highest risk, creating sustained demand for long-term disease management solutions.

Restraint - High Reliance on Long-Term Corticosteroids and Associated Risks

Corticosteroids remain the primary first-line treatment because they rapidly reduce inflammation and prevent severe complications such as vision loss. Prolonged steroid use is associated with multiple adverse effects, including osteoporosis, diabetes, hypertension, cataracts, infections, and cardiovascular complications. Elderly patients are particularly vulnerable to these side effects, increasing hospitalization risks and treatment discontinuation rates.

The high economic burden of chronic corticosteroid management and monitoring limits treatment efficiency in many healthcare settings. Patients often require continuous follow-up visits, bone protection therapies, and additional medications to manage steroid-induced complications, increasing overall healthcare costs substantially. Limited access to advanced biologic alternatives in low-income and developing regions also contributes to continued steroid dependency despite growing awareness of associated risks.

Opportunity - Expansion of Steroid-Sparing Oral and Subcutaneous Options

Healthcare providers are increasingly seeking alternatives that reduce dependence on long-term corticosteroids while maintaining disease remission and minimizing relapse rates. Advanced biologics, IL-6 inhibitors, and emerging JAK inhibitors are gaining strong clinical interest because they offer improved safety profiles and targeted immune modulation.

The availability of oral and self-administered subcutaneous formulations is improving treatment convenience and long-term adherence among elderly patients. Pharmaceutical companies are accelerating research and development to introduce innovative therapies that can significantly enhance patient outcomes and reduce glucocorticoid-related complications worldwide.

Growing investments in precision medicine and biologic drug development are expected to create substantial commercial opportunities across global healthcare markets. Regulatory agencies, including the U.S. FDA and European Medicines Agency, are supporting innovation through orphan drug designations and accelerated approval pathways for rare inflammatory diseases. Increasing patient preference for home-based treatment administration is also driving demand for convenient subcutaneous biologic therapies that reduce reliance on hospitals.

Treatment Type Insights

Corticosteroid therapy is expected to lead the giant cell arteritis treatment market, accounting for approximately 50% of revenue in 2026, driven by its rapid anti-inflammatory action and strong recommendation as the first-line treatment for newly diagnosed patients. Clinical guidelines from rheumatology associations continue to recommend corticosteroid-based induction therapy as the standard initial management approach. A notable example includes prednisone, which remains one of the most commonly prescribed therapies for giant cell arteritis worldwide.

Monoclonal antibodies are likely to represent the fastest-growing segment, supported by rising demand for steroid-sparing therapies with improved long-term safety profiles. Increasing awareness regarding glucocorticoid-related complications has encouraged physicians to adopt targeted biologics capable of reducing relapse frequency and cumulative steroid exposure. For example, tocilizumab, an IL-6 inhibitor widely used to manage giant cell arteritis and reduce corticosteroid dependency.

Route of Administration Insights

Oral administration is projected to lead the market, capturing around 60% of the revenue share in 2026. Oral medications are preferred for their ease of administration, strong patient compliance, lower hospitalization requirements, and suitability for long-term disease management. Physicians commonly prescribe oral therapies during both acute and maintenance treatment phases because they allow flexible dosage adjustment and effective symptom control. For instance, upadacitinib, an oral JAK inhibitor, is being explored for the treatment of inflammatory and autoimmune conditions, including giant cell arteritis.

The subcutaneous segment is likely to be the fastest-growing route of administration, driven by increasing adoption of biologic therapies requiring targeted immune delivery. These administration methods are gaining popularity because they improve therapeutic precision, support sustained remission, and reduce dependence on prolonged corticosteroid use. A notable example is subcutaneous tocilizumab, which has gained widespread clinical acceptance for the management of giant cell arteritis.

North America Giant Cell Arteritis Treatment Market Trends

North America is anticipated to be the leading region, accounting for a market share of 43% in 2026, driven by strong healthcare infrastructure, advanced rheumatology networks, and rapid adoption of biologic therapies. The rising prevalence of autoimmune and age-related inflammatory diseases among elderly populations continues to increase treatment demand across the region. For example, F. Hoffmann-La Roche Ltd., whose biologic therapy Actemra/Tocilizumab continues to witness strong adoption across North America for giant cell arteritis management.

U.S. Giant Cell Arteritis Treatment Market Trends

The U.S. dominates the regional market, driven by high healthcare expenditure and strong biologic adoption rates. The country has a large elderly population vulnerable to giant cell arteritis and related vasculitis disorders. Increasing FDA support for orphan and autoimmune disease therapies is accelerating innovation in targeted biologics and JAK inhibitors. Advanced rheumatology centers and strong insurance coverage improve patient access to specialized treatments.

Canada Giant Cell Arteritis Treatment Market Trends

Canada is a significant market for giant cell arteritis treatment, supported by improving access to biologics and specialty healthcare services. Rising awareness regarding inflammatory vascular disorders among elderly patients is supporting earlier diagnosis and treatment adoption. Canadian rheumatology associations are increasingly encouraging the use of advanced therapies for long-term disease management. Expansion of public healthcare coverage for autoimmune therapies is improving patient accessibility across provinces.

Europe Giant Cell Arteritis Treatment Market Trends

Europe is likely to be a significant market for giant cell arteritis treatment in 2026, due to the increasing prevalence of age-related autoimmune disorders and strong government-supported healthcare systems. The region benefits from advanced rheumatology research, early disease screening programs, and high adoption of biologic therapies for chronic inflammatory diseases. For instance, Novartis continues to strengthen its immunology and inflammatory disease portfolio across Europe.

U.K. Giant Cell Arteritis Treatment Market Trends

The U.K. is a significant market for giant cell arteritis treatment, supported by growing awareness of autoimmune inflammatory conditions and aging demographics. The National Health Service continues to expand support for advanced biologic treatment accessibility among eligible patients. Rheumatology specialists are increasingly focusing on reducing long-term corticosteroid exposure through targeted immune therapies. Healthcare institutions are promoting earlier diagnosis through vascular imaging and specialist referral pathways.

Germany Giant Cell Arteritis Treatment Market Trends

Germany dominates the regional market, driven by its advanced healthcare infrastructure and strong rheumatology expertise. The country has a growing elderly population, increasing the prevalence of inflammatory vascular diseases. Hospitals and specialty clinics are rapidly adopting biologic therapies for chronic autoimmune disease management. Germany also supports extensive clinical research activities related to immunology and targeted therapies. Increasing use of advanced imaging diagnostics, such as PET and MRI, is enhancing the early detection of giant cell arteritis.

Asia Pacific Giant Cell Arteritis Treatment Market Trends

The Asia Pacific region is likely to be the fastest-growing region in the giant cell arteritis treatment in 2026, driven by rapidly aging populations, expanding healthcare infrastructure, and increasing awareness regarding autoimmune diseases. Pharmaceutical companies are strengthening regional manufacturing and research capabilities to address the rising demand for targeted therapies. For example, AbbVie Inc., which continues expanding its immunology and inflammatory disease portfolio across Asia Pacific.

China Giant Cell Arteritis Treatment Market Trends

China dominates the regional market, driven by expanding healthcare infrastructure and rising awareness regarding autoimmune diseases. The country’s aging population is significantly increasing demand for inflammatory disease therapies and specialized rheumatology services. Increasing domestic production of biosimilars is helping reduce treatment costs and improve therapy availability.

India Giant Cell Arteritis Treatment Market Trends

India is a significant market for giant cell arteritis treatment, supported by improving healthcare awareness and increasing access to specialty treatment services. Rising elderly population levels and greater recognition of autoimmune disorders are supporting diagnosis rates nationwide. Hospitals and rheumatology centers are increasingly adopting biologic therapies and targeted immune treatments for chronic inflammatory disease management.

The global giant cell arteritis treatment market exhibits a moderately fragmented structure, driven by increasing demand for targeted biologic therapies, expanding clinical research activities, and rising focus on steroid-sparing treatment approaches for long-term disease management. The market is evolving rapidly due to advancements in immunology, increasing approvals for biologics and JAK inhibitors, and growing investment in autoimmune disease therapeutics.

With key leaders including F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis, Kiniksa Pharmaceuticals, Ltd., and Eli Lilly and Company, the competitive environment continues to intensify as companies focus on expanding biologic portfolios and developing next-generation therapies for inflammatory and autoimmune diseases. These players compete through product innovation, advanced biologic development, regulatory approvals, strategic partnerships, and expansion of global clinical trial networks.

Key Industry Developments:

• In April 2025, AbbVie received U.S. FDA approval for RINVOQ (upadacitinib) for the treatment of adults with Giant Cell Arteritis, making it the first and only oral JAK inhibitor approved for the condition in the United States.
• In April 2025, Organon acquired U.S. regulatory and commercial rights to TOFIDENCE (tocilizumab-bavi), a biosimilar to ACTEMRA, strengthening its immunology and biosimilars portfolio for the treatment of giant cell arteritis and other inflammatory diseases.